Document:

Exhibits 4.104

 

Deed of Adherence

 

THIS DEED OF ADHERENCE (this “Agreement”) dated as of June 30, 2010 is made by and among GM Investment Company
Limited, a company incorporated in Hong Kong (“GM Investment”),  Sinowill Holding Limited, a company incorporated in the British Virgin Islands
(“Sinowill”), Huge Harvest Enterprises Limited,
a company incorporated in the British Virgin Islands
(“Huge Harvest”), Kingstate Group Limited,
a company incorporated in the British Virgin Islands
(“Kingstate”), Trend Focus Limited,
a company incorporated in the British Virgin Islands
(“Trend Focus”), Funtalk China Holdings
Limited,
an exempted limited company incorporated in the Cayman Islands (the “Company”), Capital Ally Investment Limited, a
company incorporated in the British Virgin Islands
(“Capital Ally”), Arch Digital Holdings
Limited, a
company incorporated in the British Virgin Islands
(“Arch”) and Michael Marks
and Bernard J. Tanenbaum III (collectively as “Middle Kingdom
Representatives”). Each of GM Investment, Sinowill, Huge Harvest, Kingstate and Trend
Focus are sometimes referred to herein as a “New
Shareholder,” and collectively as the “New
Shareholders.”

 

WHEREAS, the Company, Capital Ally, Arch and Middle Kingdom Representatives
have entered into that certain Voting Agreement dated as of July 9,
2009 (the “Voting Agreement”).

 

WHEREAS, Capital Ally desires to transfer an
aggregate of 30,150,000 ordinary shares, par value $0.001, of the Company (the “Transferred Shares”), to the New Shareholders on June 30, 2010.

 

WHEREAS, the
New Shareholders, the Company, Capital Ally, Arch and Middle Kingdom
Representatives have agreed that the New Shareholders shall execute this
Agreement confirming their agreements to be bound by the provisions of the
Voting Agreement, with all
of the rights and obligations of “Pypo
Shareholders” of “Voting Shares” thereunder
(as such terms are defined in the Voting
Agreement).

 

NOW IT IS AGREED AS FOLLOWS:

 

Section 1.               Adherence to Voting
Agreement.  Each New Shareholder hereby agrees with each party to the Voting Agreement
that it will comply with and be bound by all of the provisions, including all
rights and obligations, of the Voting Agreement (a copy of which has been delivered to each New Shareholder and
is attached hereto as Annex A  for identification) in all respects as if each New Shareholder were
a party to the Voting Agreement and were named therein as a party,
and on the basis that references therein to “Pypo
Shareholder” shall include a separate
reference to the New Shareholder, and the Transferred Shares,
together with all the shares of voting securities in the Company held by the
New Shareholder, whether now owned or hereafter acquired, including, but not
limited to, any Earn-Out Shares, as such term is defined in the Agreement and
Plan of Merger, Conversion and Share Exchange, as amended, by and among the
Company, Capital Ally, Arch and certain other parties, dated as of September 5,
2009, transferred by Capital Ally to the New Shareholder hereafter, shall constitute “Voting
Shares” as defined therein.

 

Section 2.               Entire Agreement.  This Agreement sets forth the entire
understanding and agreement of each New Shareholder, the Company,
Capital Ally, Arch and Middle Kingdom Representatives with respect to the transactions contemplated hereby and
supersedes and

 

1

 

replaces any prior understanding,
agreement or statement of intent, in each case written or oral, of any kind and
every nature with respect hereto. Any provision of this Agreement can only be amended or
modified in whole or in part by an agreement in writing executed by each New
Shareholder, the Company, Capital Ally, Arch and Middle Kingdom
Representatives.

 

Section 3.               Governing Law.  This Agreement and the
legal relations among the parties shall be governed by, and construed in
accordance with, the laws of the
State
of New
York regardless of the laws that might otherwise govern under applicable
principles of conflicts of laws thereof, except to the extent the laws of New
York are mandatorily applicable to the transactions hereunder.

 

Section 4.               Counterparts.  This Agreement may be executed in any number
of counterparts, each of which shall be deemed to be an original and all of
which together shall be deemed to be one and the same instrument.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGES FOLLOW]

 

2

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the date first above written.

 

 

	
   

  	
  Funtalk China Holdings Limited

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Dongping Fei

  
	
   

  	
  Name:

  	
  Dongping Fei

  
	
   

  	
  Title:

  	
  Director

  

 

[Signature Page to Deed of Adherence]

 

 

	
   

  	
  GM Investment Company Limited

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Kam Yuen

  
	
   

  	
  Name:

  	
  Kam Yuen

  
	
   

  	
  Title:

  	
  Director

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Sinowill Holding Limited

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Nana Gong

  
	
   

  	
  Name:

  	
  Nana Gong

  
	
   

  	
  Title:

  	
  Director

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Huge Harvest Enterprises
  Limited

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Dongping Fei

  
	
   

  	
  Name:

  	
  Dongping Fei

  
	
   

  	
  Title:

  	
  Director

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Kingstate Group Limited

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Hengyang Zhou

  
	
   

  	
  Name:

  	
  Hengyang Zhou

  
	
   

  	
  Title:

  	
  Director

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Trend Focus Limited

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Kuo Zhang

  
	
   

  	
  Name:

  	
  Kuo Zhang

  
	
   

  	
  Title:

  	
  Director

  

 

[Signature Page to Deed of Adherence]

 

 

	
   

  	
  Capital
  Ally Investment Limited

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Kam Yuen

  
	
   

  	
  Name:

  	
  Kam Yuen

  
	
   

  	
  Title:

  	
  Director

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Arch
  Digital Holdings Limited

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Clement Kwong

  
	
   

  	
  Name:

  	
  Clement Kwong

  
	
   

  	
  Title:

  	
  Director

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Michael
  Marks

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Michael Marks

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Bernard
  J. Tanenbaum III

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Bernard J. Tanenbaum III

  

 

[Signature Page to Deed of Adherence]

 

 

Annex A

 

Voting AgreementAnavex Life Sciences Corp.: Exhibit 10.1 - Filed by newsfilecorp.com

THIS SHARES FOR SERVICE AND SUBSCRIPTION AGREEMENT RELATES
TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT
U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT").

NONE OF THE SECURITIES TO WHICH THIS SHARES FOR SERVICE AND
SUBSCRIPTION AGREEMENT RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT, OR ANY
U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR
SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS
DEFINED IN REGULATION S OF THE 1933 ACT) EXCEPT IN ACCORDANCE WITH THE
PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE
CONDUCTED UNLESS IN ACCORDANCE WITH THE 1933 ACT. 

SHARES FOR SERVICE AND SUBSCRIPTION AGREEMENT 

                            This
SHARES FOR SERVICE AND SUBSCRIPTION AGREEMENT (the “Agreement”) is made as of
July 5, 2010, by and between Anavex Life Sciences Corp. (the “Company”), and
Eurogenet Labs SA. (“EUROGENET”). 

RECITALS 

                            WHEREAS:

              A.     
    The Company is indebted to EUROGENET for past services ,
and, in consideration for said services, (the “Services”), the Company agrees to
pay EUROGENET US$1,000,000 or a number of units of the Company. Each unit
consisting of one common share and one half common share purchase warrant. Each
full warrant and $3.50 is required to purchase one share of the Company for a
period of 18 months from date of issue. Each Unit is valued at $2.50. 

NOW, THEREFORE, the parties hereto agree as follows: 

1.         
Issuance of the Shares 

1.1        In consideration
for the Services provided to the Company under the Service Agreement, the
Company hereby agrees to grant to EUROGENET and EUROGENET hereby irrevocably
subscribes for and agrees to purchase 400,000 Units of the (the "Units"), in
full and final payment of the amount owed to EUROGENET by the Company for
services rendered.

1.2        The Company
agrees to issue to EUROGENET a certificate representing the Shares as soon as
practicable following delivery by EUROGENET to the Company of a fully-executed
copy of this Agreement. 

2.          Acknowledgements
  of EUROGENET

2.1        EUROGENET
acknowledges and agrees that: 

(a)        none of the Shares
have been registered under the 1933 Act, or under any state securities or “blue
sky” laws of any state of the United States, and, unless so registered, may not
be offered or sold in the United States or, directly or indirectly, to U.S.
Persons, as that term is defined in Regulation S under the 1933 Act (“Regulation
S”), except in accordance with the provisions of Regulation S, pursuant to an
effective registration statement under the 1933 Act, or pursuant to an exemption
from, or in a transaction not subject to, the registration requirements of the
1933 Act; 

(c)        the Company has not
undertaken, and will have no obligation, to register any of the Shares under the
1933 Act; 

2 

(d)        the decision to
execute this Agreement and acquire the Shares hereunder has not been based upon
any oral or written representation as to fact or otherwise made by or on behalf
of the Company, and such decision is based entirely upon a review of information
(the receipt of which is hereby acknowledged) which has been filed by the
Company with the United States Securities and Exchange Commission and in
compliance, or intended compliance, with applicable securities legislation
(collectively, the “Public Record”); 

(e)        no securities
commission or similar regulatory authority has reviewed or passed on the merits
of the Shares; 

(f)        there is no
government or other insurance covering the Shares; 

(g)        EUROGENET and
its advisor(s) have had a reasonable opportunity to ask questions of and receive
answers from the Company in connection with the distribution of the Shares
hereunder, and to obtain additional information, to the extent possessed or
obtainable without unreasonable effort or expense, necessary to verify the
accuracy of the information about the Company; 

(h)        the books and
records of the Company were available upon reasonable notice for inspection,
subject to certain confidentiality restrictions, by EUROGENET during reasonable
business hours at its principal place of business, and all documents, records
and books in connection with the distribution of the Shares hereunder have been
made available for inspection by EUROGENET, its attorney and/or advisor(s); 

(i)        the Company is
entitled to rely on the representations, warranties, statements and answers of
EUROGENET contained in this Agreement; 

(j)        EUROGENET will
indemnify and hold harmless the Company and, where applicable, its directors,
officers, employees, agents, advisors and shareholders, from and against any and
all loss, liability, claim, damage and expense whatsoever (including, but not
limited to, any and all fees, costs and expenses whatsoever reasonably incurred
in investigating, preparing or defending against any claim, lawsuit,
administrative proceeding or investigation whether commenced or threatened)
arising out of or based upon any representation or warranty of EUROGENET
contained herein or in any document furnished by EUROGENET to the Company in
connection herewith being untrue in any material respect or any breach or
failure by EUROGENET to comply with any covenant or agreement made by EUROGENET
to the Company in connection therewith; 

(k)        none of the Shares
are listed on any stock exchange or automated dealer quotation system and no
representation has been made to EUROGENET that any of the Shares will become
listed on any stock exchange or automated dealer quotation system; except that
currently the common shares of the Company are quoted for trading on the OTC
Bulletin Board; 

(l)        offers and
sales of any of the Shares shall be made only in compliance with the
registration provisions of the 1933 Act or an exemption therefrom; 

(m)        the Company
will refuse to register any transfer of the Shares not made in accordance with
the provisions of Regulation S, pursuant to an effective registration statement
under the 1933 Act or pursuant to an available exemption from the registration
requirements of the 1933 Act; and, 

(n)        EUROGENET has
been advised to consult its own legal, tax and other advisors with respect to
the merits and risks of an investment in the Shares and with respect to
applicable resale restrictions, and it is solely responsible (and the Company is
not in any way responsible) for compliance with: 

	 	(i) 	
      any applicable laws of the jurisdiction in which
      EUROGENET is resident in connection with the distribution of the Shares
      hereunder; and

	 	 	 
	 	(ii) 	
      applicable resale
restrictions.

3 

3.1        Representations,
  Warranties and Covenants of EUROGENET

              EUROGENET
hereby represents and warrants to and covenants with the Company (which
representations, warranties and covenants shall survive the closing) that: 

(a)        it is not resident
in the United States; 

(b)        it has received and
carefully read this Agreement; 

(c)        it is duly
incorporated and validly subsisting under the laws of its jurisdiction of
incorporation and all necessary approvals by its directors, shareholders and
others have been obtained to authorize execution and performance of this
Agreement on behalf of EUROGENET; 

(d)        it has the legal
capacity and competence to enter into and execute this Agreement and to take all
actions required pursuant hereto; 

(e)        it has duly executed
and delivered this Agreement and this Agreement constitutes a valid and binding
agreement of EUROGENET enforceable against EUROGENET; 

(f)        the entering into of
this Agreement and the transactions contemplated hereby do not result in the
violation of any of the terms and provisions of any law applicable to, or, if
applicable, the constating documents of, EUROGENET, or of any agreement, written
or oral, to which EUROGENET may be a party or by which EUROGENET is or may be
bound; 

(g)        EUROGENET (i)
has adequate net worth and means of providing for its current financial needs
and possible personal contingencies, (ii) has no need for liquidity in this
investment, and (iii) is able to bear the economic risks of an investment in the
Shares for an indefinite period of time, and can afford the complete loss of
such investment; 

(h)        EUROGENET is
aware that an investment in the Company is speculative and involves certain
risks, including the possible loss of the investment, and EUROGENET has
carefully read and considered the matters set forth under the caption “Risk
Factors” appearing in the Company’s most recent quarterly report on Form 10-QSB
filed with the SEC; 

(i)        it has the requisite
knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of the investment in the Shares and the Company;

(j)        it understands
and agrees that the Company and others will rely upon the truth and accuracy of
the acknowledgements, representations and agreements contained in this
Agreement, and agrees that if any of such acknowledgements, representations and
agreements are no longer accurate or have been breached, it shall promptly
notify the Company; 

(k)        the
acknowledgements, representations and agreements contained in this Agreement are
complete and accurate and may be relied upon by the Company, and EUROGENET will
notify the Company immediately of any material change in any such information
occurring prior to the closing of the acquisition of the Shares; 

(l)        it is purchasing the
Shares for its own account for investment purposes only and not for the account
of any other person and not for distribution, assignment or resale to others,
and no other person has a direct or indirect beneficial interest in such Shares,
and it has not subdivided its interest in the Shares with any other person; 

(m)        it is not an
underwriter of, or dealer in, the common shares of the Company, nor is it
participating, pursuant to a contractual agreement or otherwise, in the
distribution of the Shares; 

(n)        it has made an
independent examination and investigation of an investment in the Shares and the
Company and has depended on the advice of its legal and financial advisors and
agrees that the Company will not be responsible in anyway whatsoever for its
decision to invest in the Shares and the Company; 

4 

(o)        it is not aware of
any advertisement of any of the Shares and is not acquiring the Shares as a
result of any form of general solicitation or general advertising including
advertisements, articles, notices or other communications published in any
newspaper, magazine or similar media or broadcast over radio or television, or
any seminar or meeting whose attendees have been invited by general solicitation
or general advertising; and, 

(p)        no person has made
to EUROGENET any written or oral representations: 

	 	(i) 	
      that any person will resell or repurchase any of the
      Shares;

	 	 	 
	 	(ii) 	
      that any person will refund the purchase price of any of
      the Shares; or,

	 	 	 
	 	(iii) 	
      as to the future price or value of any of the
    Shares.

3.2        In this
Agreement, the term “U.S. Person” shall have the meaning ascribed thereto in
Regulation S and for the purpose of the Agreement includes any person in the
United States. 

4.          Acknowledgement
  and Waiver

4.1        EUROGENET
has acknowledged that the decision to purchase the Shares was solely made on the
basis of publicly available information contained in the Public Record.
EUROGENET hereby waives, to the fullest extent permitted by law, any rights of
withdrawal, rescission or compensation for damages to which EUROGENET might be
entitled in connection with the distribution of any of the Shares. 

5.        
 Legending of Subject Shares 

5.1        EUROGENET hereby
acknowledges that that upon the issuance thereof, and until such time as the
same is no longer required under the applicable securities laws and regulations,
the certificates representing any of the Shares will bear legends in
substantially the following forms: 

  
    THESE SECURITIES WERE ISSUED IN AN OFFSHORE TRANSACTION
      TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION
      S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933
      ACT"). ACCORDINGLY, NONE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER
      THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED,
      NONE MAY BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES
      OR TO U.S. PERSONS (AS DEFINED IN REGULATION S OF THE 1933 ACT) EXCEPT IN
      ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT
      TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO
      AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
      REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE
      STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES
      MAY NOT BE CONDUCTED UNLESS IN ACCORDANCE WITH THE 1933 ACT. 

  

5.2        EUROGENET hereby
acknowledges and agrees to the Company making a notation on its records or
giving instructions to the registrar and transfer agent of the Company in order
to implement the restrictions on transfer set forth and described in this
Agreement. 

5.3        The Subscriber
hereby acknowledges and agrees that he has been advised by the Company to
consult with his own legal counsel or advisors to determine the resale
restrictions that may be applicable to him. 

5.4        The Subscriber
hereby acknowledges, agrees and instructs that the certificates representing the
Shares will not bear legends relating to CaEurogenetian securities laws. 

5 

6.        
 Costs 

6.1        EUROGENET
acknowledges and agrees that all costs and expenses incurred by EUROGENET
(including any fees and disbursements of any special counsel retained by
EUROGENET) relating to the acquisition of the Shares shall be borne by
EUROGENET. 

7.          Governing
  Law

7.1        This
Agreement shall be construed and enforced in accordance with and governed by the
laws of the State of Nevada, without reference to principles of conflicts or
choice of law thereof. Each of the parties consents and attorns to the
jurisdiction of the U.S. District Court in the State of Nevada. 

8.        
 Survival 

8.1        This
Agreement, including without limitation the representations, warranties and
covenants contained herein, shall survive and continue in full force and effect
and be binding upon the parties hereto notwithstanding the completion of the
purchase of the Shares by EUROGENET pursuant hereto. 

9.        
 Assignment 

9.1        This Agreement is
not transferable or assignable. 

10.       
Counterparts and Electronic Means 

10.1      This Agreement may be
executed in several counterparts, each of which will be deemed to be an original
and all of which will together constitute one and the same instrument. Delivery
of an executed copy of this Agreement by electronic facsimile transmission or
other means of electronic communication capable of producing a printed copy will
be deemed to be execution and delivery of this Agreement as of the date first
above written. 

11.      
 Severability 

11.1      The invalidity or
unenforceability of any particular provision of this Agreement shall not affect
or limit the validity or enforceability of the remaining provisions of this
Agreement. 

12.        Entire
Agreement 

12.1      Except as expressly provided
in this Agreement and in the agreements, instruments and other documents
contemplated or provided for herein, this Agreement contains the entire
agreement between the parties with respect to the subject matter hereof and
there are no other terms, conditions, representations or warranties, whether
expressed, implied, oral or written, by statute or common law, by the Company or
by anyone else. 

IN WITNESS WHEREOF the parties hereto have duly executed
this Agreement as of the date first above written. 

	ANAVEX LIFE SCIENCES CORP. 	EUROGENET LABS SA. 
	  	  
	By: /s/ Harvey Lalach 	/s/ Dimitrios Fousekis 
	  	  
	Name:  Harvey Lalach	Dimitrios Fousekis 
	Title:  President, CFO, Secretary and Director 	Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}]]